Baird Positive on Celgene (CELG) As Pancreatic Cancer Drug Shows Promise

December 3, 2012 9:00 AM EST Send to a Friend
Get Alerts CELG Hot Sheet
Price: $92.57 +3.48%

Rating Summary:
    22 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 15 | Down: 16 | New: 67
Trade CELG Now!
Join SI Premium – FREE
A recent report by Baird suggests big potential for Celgene Corporation's (Nadaq: CELG) Abraxane in pancreatic cancer. Prior to recent Phase III news, 18 percent of physicians identified Abraxane as a promising new treatment strategy for pancreatic cancer, and the numbers were trending positive.

"Bottom line here is given limited current treatment options, and assuming what we expect will be a meaningful OS benefit shown versus Gemzar this January (at ASCO GI), we estimate pancreatic cancer could reasonably be $1B peak revenue opportunity," said analyst Christopher J. Raymond.

Baird has an Outperform rating on Celgene (NASDAQ: CELG) with a price target of $92.00.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $78.59 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Robert W Baird

Add Your Comment